Keywords : Glomerulonephritis, renal disease
This report provides data on the therapeutic development for Glomerulonephritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Glomerulonephritis. 'Glomerulonephritis - Pipeline Review, H1 2012' is built using data and information sourced from Global Industries Direct’s proprietary databases, Firms /University websites, SEC fili...
More »
Search ReportLinker
The Largest Collection of Market Research Reports
» 1.2 Million Industry Reports
» 450,000 Company Profiles
» 850,000 Market Briefings
» 40,000 Country Guides
From +200,000 authoritative sources
This report provides data on the therapeutic development for Glomerulonephritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Glomerulonephritis. 'Glomerulonephritis - Pipeline Review, H1 2012' is built using data and information sourced from Global Industries Direct’s proprietary databases, Firms /University websites, SEC filings, investor presentations and featured press releases from firm /university sites and market -specific third party sources, put together by Global Industries Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope of the Research
- A snapshot of the global therapeutic scenario for Glomerulonephritis.
- A review of the Glomerulonephritis products under development by industry players and universities/research institutes based on information derived from industry player and market -specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Glomerulonephritis pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage new product development featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Glomerulonephritis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and take over s effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Glomerulonephritis pipeline depth and focus of Glomerulonephritis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and grow business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Pathology Industry in Japan
Table of Contents
Data table of Contents
Data table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global March kets Direct Report Coverage 6
Glomerulonephritis Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Glomerulonephritis 8
Glomerulonephritis Therapeutics under Development by Firms 10
Glomerulonephritis Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Pre-Clinical Stage Products 15
Comparative Analysis 15
Glomerulonephritis Therapeutics – Products under Development by Firms 16
Glomerulonephritis Therapeutics – Products under Investigation by Universities/Institutes 17
Companies Involved in Glomerulonephritis Therapeutics Development 18
Baxter International Inc. 18
Optherion, Inc. 19
Alexion Pharmaceuticals, Inc. 20
Pharmalink AB 21
Ferring Pharmaceuticals, Inc. 22
Glomerulonephritis – Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Combination Products 24
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 30
Nefecon - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Soliris - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Recombinant Protective Human CFH - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Tetracosactide Hexacetaat - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Aliskiren - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Rituximab - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Mycophenolate Mofetil + Irbesartan - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Pentoxifylline - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Rituximab + Abatacept - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Rituximab + Tocilizumab - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Myfortic + Prednisolone - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
MIF Inhibitors - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Ramipril - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Sirolimus + Enalapril + Atorvastatin - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Anti-MIF Antibody - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Glomerulonephritis Therapeutics – Drug Profile Updates 48
Glomerulonephritis Therapeutics – Discontinued Products 52
Glomerulonephritis Therapeutics - Dormant Products 53
Glomerulonephritis – Product Development Milestones 54
Featured News & Press Releases 54
October 13, 2010: Pharmalink Receives US Orphan Drug Designation For Nefecon 54
October 26, 2009: Japanese Patent granted for Pharmalink AB's Nefecon 54
April 29, 2009: Pharmalink AB Completes Phase II Clinical Study With Renal Disease Drug Nefecon 55
March 31, 2008: Pharmalink Reports Promising Interim Results From Phase II Trials For New Renal Disease Drug Nefecon 55
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 58
Disclaimer 58
List of Tables
List of Tables
Number of Products Under Development for Glomerulonephritis, H1 2012 8
Products under Development for Glomerulonephritis – Comparative Analysis, H1 2012 9
Number of Products under Development by Firms, H1 2012 10
Number of Products under Investigation by Universities/Institutes, H1 2012 11
Comparative Analysis by Late Stage Development, H1 2012 12
Comparative Analysis by Mid Clinical Stage Development, H1 2012 13
Comparative Analysis by Early Clinical Stage Development, H1 2012 14
Comparative Analysis by Pre-Clinical Stage Development, H1 2012 15
Products under Development by Firms, H1 2012 16
Products under Investigation by Universities/Institutes, H1 2012 17
Baxter International Inc., H1 2012 18
Optherion, Inc., H1 2012 19
Alexion Pharmaceuticals, Inc., H1 2012 20
Pharmalink AB, H1 2012 21
Ferring Pharmaceuticals, Inc., H1 2012 22
Assessment by Monotherapy Products, H1 2012 23
Assessment by Combination Products, H1 2012 24
Assessment by Stage and Route of Administration, H1 2012 26
Assessment by Stage and Molecule Type, H1 2012 29
Glomerulonephritis Therapeutics – Drug Profile Updates 48
Glomerulonephritis Therapeutics – Discontinued Products 52
Glomerulonephritis Therapeutics – Dormant Products 53
List of Figures
List of Figures
Number of Products under Development for Glomerulonephritis, H1 2012 8
Products under Development for Glomerulonephritis – Comparative Analysis, H1 2012 9
Products under Development by Firms, H1 2012 10
Products under Investigation by Universities/Institutes, H1 2012 11
Late Stage Products, H1 2012 12
Mid Clinical Stage Products, H1 2012 13
Early Clinical Stage Products, H1 2012 14
Pre-Clinical Stage Products, H1 2012 15
Assessment by Monotherapy Products, H1 2012 23
Assessment by Combination Products, H1 2012 24
Assessment by Route of Administration, H1 2012 25
Assessment by Stage and Route of Administration, H1 2012 26
Assessment by Molecule Type, H1 2012 27
Assessment by Stage and Molecule Type, H1 2012 28
